Drug · Small Molecule

Lestaurtinib

CI-DRUG-00000337Explore in graph →NCIt C48402 CHEMBL603469 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	7	—	—	2003-08
Leukemia	Phase3	Phase 3	1	4	—	—	2003-10
Malignant Prostate Neoplasm	Phase2	Phase 2	0	1	—	—	2004-03

Computedclinicaltrials

Curated evidence

Clinical evidence (16)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–16 of 16 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 D593del1
Crenolanib +

Clinical trials

Trials with this intervention (7)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–7 of 7 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00557193	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	completed	Phase 3	218	Children's Oncology GroupNETWORK	4	Jul 15, 2024	clinicaltrials
NCT00084422	N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	completed

Molecule

Record

Kind: Small Molecule
Mechanism: Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; NT-3 growth factor receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor
Targets: 6 genes
Aliases: 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-, A-154475, A-154475.0, CEP 701, CEP-701, CEP701, KT-555, KT-5555, KT5555, Lestaurtinib, SP-924, SP924, SPM-924

Data updated 22 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.

FLT3 D835 & I8361
FLT3/ABL/Aurora Kinase Inhibitor KW-2449 + Lestaurtinib + Quizartinib + SorafenibSubstitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID8925 In this study, records of 69 FLT3 mutated AML patients treated with different FLT3 inhibitors were analyzed for emergence of new mutations. Before the start of therapy with a FLT3 inhibitor, 60 (87%) … (full text at CIViC) PMID 24737502 · Alvarado et al., 2014 · Open in CIViC	civic

FLT3 D835 & I8361

FLT3/ABL/Aurora Kinase Inhibitor KW-2449 + Lestaurtinib + Quizartinib + SorafenibSubstitutes

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Does Not Support Sensitivity Response

submitted

EID8925

In this study, records of 69 FLT3 mutated AML patients treated with different FLT3 inhibitors were analyzed for emergence of new mutations. Before the start of therapy with a FLT3 inhibitor, 60 (87%) … (full text at CIViC)

PMID 24737502 · Alvarado et al., 2014 · Open in CIViC

FLT3 D835Y2
Lestaurtinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID11095 Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC	civic
Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Lestaurtinib + MidostaurinSubstitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID11085 A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC	civic

FLT3 ITD2
Lestaurtinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID297 CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations. PMID 14726387 · Smith et al., 2004 · Open in CIViC	civic
AG1295 + AGS324 + Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + KW2449 + Lestaurtinib + Linifanib + Midostaurin + Ponatinib + Quizartinib + R406 + Sorafenib + SunitinibSubstitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11084 A panel of FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3-ITD using MTT growth/survival assay. Each of the 13 TKIs inhibited proliferation of FLT3-ITD cells in a … (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC	civic

FLT3 Y572del2
Lestaurtinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID12861 Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to lestaurtinib and was 5 to 10-fold more sensitive than the FLT3-ITD construct (Figure 4). PMID 33914060 · Young et al., 2021 · Open in CIViC	civic
Crenolanib + Lestaurtinib + Midostaurin + Ponatinib + Quizartinib + SorafenibSubstitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	5	submitted	EID9306 The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC) PMID 33914060 · Young et al., 2021 · Open in CIViC	civic